V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ......

5
WORKING DOCUMENT November 2017 | 1 V3P: Region Fact Sheet This regional fact sheet is intended for use by MoH and vaccine procurement staff. The regional fact sheet provides information on all vaccines procured by SEAR including analyses of: the presentations used in SEAR compared to the rest of the world; the procurement methods used in SEAR compared to the rest of the world; value to the market of the most frequently reported vaccines to the V3P from SEAR and the rest of the world; prices paid by SEAR, compared to rest of the world. Increased knowledge about several aspects of vaccine market and purchasing may help to inform the development of policies related to market shaping and vaccine access. The Vaccine Product Price & Procurement (V3P) initiative was launched to provide all countries with a platform for greater vaccine price & procurement transparency. The initiative collects data through the WHO and UNICEF Joint Reporting Form, and analyses and distributes information to relevant stakeholders to inform policy making and procurement processes. As of July 2017, the database contained data from 142 countries. The fact sheet is exclusively based on the data reported through the JRF & V3P initiative, as of July 2017. Pool-procurement refers to vaccines procured through UNICEF SD and the PAHO Revolving Fund. Readers may access additional vaccine price and procurement information from reporting countries and procurement agencies (UNICEF and PAHO) on the V3P website (http://www.who.int/immunization/ v3p) or by contacting v3p-project@ who.int. SEAR 1 SEAR countries contributing to the V3P: Bangladesh, Bhutan, Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste. Highlights The SEAR 1 region market is 35% of the global market in volume and 8% in value. The regional vaccine procurement habits are different from the rest of the world in several ways, which may serve to inform sustainable supply strategies: • lower number of vaccine types, with 19 vaccine types compared to 58 reported from all other regions; • higher use of multi- versus single-dose presentations; • lesser use of prefilled syringes than in the rest of the world; • an absence of mixed-procuring countries; • very high relative value of BCG and DTP-HepB-Hib vaccines in SEAR, compared to the non-SEAR market; • three vaccines analysed for price suggest that: » WAPs in non-Gavi MICs may be lower in SEAR than in non-Gavi, non- PAHO MICs in the rest of the world; » non-Gavi MICs in SEAR purchase in variable volumes compared to non- Gavi, non-PAHO MICs in the rest of the world. Vaccine Market For the data in the V3P database, the size of the vaccine market in SEAR is 35% of the global market by volume, but only about 8% by value. This is predominantly related to the overall size of the SEAR region, which is the most populous of all regions. However, a majority of HICs from Western Europe do not report price data to the V3P, so the relative size of the global market is higher. The global top 10 vaccines by value are PCV, HPV, Rota, Influenza (seasonal – adult), Varicella, DTP-HepB-Hib, MenA,C,Y,W-135 conj, MenC, DTaP-HepB-Hib- IPV, and BCG, and these 10 account for about 49% of the value of the market in SEAR. The relative value of each vaccine type, in each market, is shown in Chart 1 (see page 2). Chart 1 also shows that the primary differences between the SEAR and the non-SEAR markets are the greater relative values of BCG and DTP-HepB- Hib in the SEAR market. These two vaccines account for about 42% of the value of the top 10 vaccines. In the non-SEAR market, the value of the top 10 vaccines is more equally distributed.

Transcript of V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ......

Page 1: V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ... populous of all regions. However, a majority of HICs from Western Europe do not report

WORKING DOCUMENT • November 2017 | 1

V3P: Region Fact Sheet

This regional fact sheet is intended for use by MoH and vaccine procurement staff. The regional fact sheet provides information on all vaccines procured by SEAR including analyses of:

• the presentations used in SEAR compared to the rest of the world;

• the procurement methods used in SEAR compared to the rest of the world;

• value to the market of the most frequently reported vaccines to the V3P from SEAR and the rest of the world;

• prices paid by SEAR, compared to rest of the world.

Increased knowledge about several aspects of vaccine market and purchasing may help to inform the development of policies related to market shaping and vaccine access.

The Vaccine Product Price & Procurement (V3P) initiative was launched to provide all countries with a platform for greater vaccine price & procurement transparency. The initiative collects data through the WHO and UNICEF Joint Reporting Form, and analyses and distributes information to relevant stakeholders to inform policy making and procurement processes. As of July 2017, the database contained data from 142 countries.

The fact sheet is exclusively based on the data reported through the JRF & V3P initiative, as of July 2017. Pool-procurement refers to vaccines procured through UNICEF SD and the PAHO Revolving Fund. Readers may access additional vaccine price and procurement information from reporting countries and procurement agencies (UNICEF and PAHO) on the V3P website (http://www.who.int/immunization/v3p) or by contacting [email protected].

SEAR

1SEAR countries contributing to the V3P: Bangladesh, Bhutan, Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste.

HighlightsThe SEAR1 region market is 35% of the global market in volume and 8% in value. The regional vaccine procurement habits are different from the rest of the world in several ways, which may serve to inform sustainable supply strategies:

• lower number of vaccine types, with 19 vaccine types compared to 58 reported from all other regions;

• higher use of multi- versus single-dose presentations;• lesser use of prefilled syringes than in the rest of the world;• an absence of mixed-procuring countries;• very high relative value of BCG and DTP-HepB-Hib vaccines in SEAR,

compared to the non-SEAR market;• three vaccines analysed for price suggest that:

» WAPs in non-Gavi MICs may be lower in SEAR than in non-Gavi, non-PAHO MICs in the rest of the world;

» non-Gavi MICs in SEAR purchase in variable volumes compared to non-Gavi, non-PAHO MICs in the rest of the world.

Vaccine MarketFor the data in the V3P database, the size of the vaccine market in SEAR is 35% of the global market by volume, but only about 8% by value. This is predominantly related to the overall size of the SEAR region, which is the most populous of all regions. However, a majority of HICs from Western Europe do not report price data to the V3P, so the relative size of the global market is higher.

The global top 10 vaccines by value are PCV, HPV, Rota, Influenza (seasonal – adult), Varicella, DTP-HepB-Hib, MenA,C,Y,W-135 conj, MenC, DTaP-HepB-Hib-IPV, and BCG, and these 10 account for about 49% of the value of the market in SEAR. The relative value of each vaccine type, in each market, is shown in Chart 1 (see page 2).

Chart 1 also shows that the primary differences between the SEAR and the non-SEAR markets are the greater relative values of BCG and DTP-HepB-Hib in the SEAR market. These two vaccines account for about 42% of the value of the top 10 vaccines. In the non-SEAR market, the value of the top 10 vaccines is more equally distributed.

Page 2: V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ... populous of all regions. However, a majority of HICs from Western Europe do not report

WORKING DOCUMENT • November 2017 | 2

SEAR

Products and PresentationsSEAR uses a smaller number of vaccine types (19) than any other WHO region (58 in non-SEAR countries). No vaccines are exclusive to SEAR.

SEAR uses five out of six presentations reported by all other regions (an intranasal sprayer is reported from non-SEAR but at a frequency of <1% - not shown). However, there is a

much lower prevalence of prefilled syringes in SEAR than in non-SEAR countries (1% versus 18%).

Chart 2 shows a greater predominance of multi-dose presentations in SEAR compared to non-SEAR countries (84% versus 48%), where 10-dose and 20-dose presentations account for 68% of all presentation sizes.

Chart 1. The relative value of the global top 10 vaccines in the SEAR and non-SEAR markets.

SEAR non-SEAR

Chart 2. Prevalence of presentation sizes in SEAR and non-SEAR countries.

SEAR non-SEAR

Page 3: V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ... populous of all regions. However, a majority of HICs from Western Europe do not report

WORKING DOCUMENT • November 2017 | 3

Procurement MethodProcurement in SEAR is split between self-procuring (45%) and pool-procurement (55%). The prevalence of pool-procurement in non-SEAR countries is similar (54%), but 16% of countries are mixed-procuring, which is absent in SEAR (see Chart 3).

Vaccine PricesThere is very limited data for non-Gavi MICs in SEAR, but for three vaccines analysed, WAPs for these countries in SEAR were 23 to 50% lower than for the same single-dose vaccines in non-Gavi, non-PAHO MICs in the non-SEAR market (see Chart 4).

Minimum, maximum, and median prices for vaccines procured in SEAR are shown in Table 1 (see page 4).

Vaccine AvailabilityReported manufacturers from SEAR and globally, for each vaccine type, are shown in Table 2 (see page 5).

Chart 4. WAPs for three select single-dose vaccines in self-procuring non-Gavi MICs in SEAR and non-Gavi, non-PAHO MICs in non-SEAR, in 20162.

2Vaccines were selected on the basis of sufficient data for analyses – data for the same presentations from at least two countries in both SEAR and non-SEAR.

Chart 3. Prevalence of procurement method in SEAR and non-SEAR countries.

SEAR

SEAR non-SEAR

Page 4: V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ... populous of all regions. However, a majority of HICs from Western Europe do not report

WORKING DOCUMENT • November 2017 | 4

Table 1. Proportion of countries self-procuring, minimum, median, and maximum prices, number of products, and number of manufacturers for each vaccine type reported from at least three SEAR countries, in 2016.

Vaccine type (ranked by frequency of use)

% o

f cou

ntrie

s se

lf-pr

ocur

ing

in

SEAR

SEAR price (all procurement methods, all income groups): lowest (presentation size) / highest (presentation size) / median N

diff

eren

t pr

oduc

ts in

SE

AR

N m

anuf

actu

rers

in

SEA

R

N m

anuf

actu

rers

re

port

ed g

loba

lly

bOPV1,3 45 $0.08 (20-dose) / $1.65 (10-dose) / $0.14 8 6 10

BCG 60 $0.05 (10-dose) / $4.96 (20-dose) / $0.14 9 7 16

IPV 38 $0.83 (10-dose) / $23.64 (5-dose) / $1.90 5 4 7

DTP-HepB-Hib 38 $0.77 (10-dose) / $6.31 (5-dose) / $1.50 5 5 11

HepB (ped) 20 $0.17 (1-dose) / $1.73 (1-dose) / $0.60 3 3 13

Measles 40 $0.17 (5-dose) / $2.33 (10-dose) / $0.28 3 2 5

MMR 50 $1.40 (10-dose) / $5.73 (2-dose) / $3.73 4 2 5

Td 50 $0.11 (10-dose) / $1.36 (10-dose) / $0.19 2 2 13

DTP 50 $0.17 (10-dose) / $0.41 (10-dose) / $0.21 3 3 8

JE 100 $0.45 (5-dose) / $7.86 (1-dose) / $0.70 3 2 5

TT 0 $0.79 (10-dose) / $0.79 (10-dose) / $0.79 1 1 14

DT 100 $0.19 (10-dose) / $1.47 (1-dose) / $0.32 2 2 11

MR 33 $0.58 (2-dose) / $0.62 (10-dose) / $0.61 1 1 3

SEAR

Page 5: V3P: Region Fact Sheet...lesser use of prefilled syringes than in the rest of the world; ... populous of all regions. However, a majority of HICs from Western Europe do not report

WORKING DOCUMENT • November 2017 | 5

Table 2. Vaccine manufacturers reported by SEAR countries, and additional manufacturers reported from other regions but not from SEAR.

Vaccine type Manufacturers reported by SEAR countries Additional manufacturers not reported by SEAR

BCG BB-NCIPD; GreenSignal Bio Pharma Limited; InterVax; Japan BCG Laboratory; PT Bio Farma (Persero); Serum Institute of India; Thai Red Cross Society

AJ Vaccines A/S; Biomed Lublin; China CNBG; FAP (Fundação Ataulpho de Paiva); Institut Pasteur Iran; Institut Pasteur Tunis; IVAC (Institute of Vaccines and Medical Biologicals); Mikrogen; Torlak Institute of Virology, Vaccines and Sera

bOPV1,3 Bharat Biotech; GSK; Haffkine Bio; PT Bio Farma (Persero); Sanofi Pasteur; Serum Institute of India

Birmex; Boryung Biopharma; China CNBG; Razi Institute Iran

DT PT Bio Farma (Persero); Serum Institute of India Arabio; BB-NCIPD; Biological E; China CNBG; InterVax; Mikrogen; Razi Institute Iran; Sanofi Pasteur; Torlak Institute of Virology, Vaccines and Sera

DTP Biological E; PT Bio Farma (Persero); Serum Institute of India

Boryung Biopharma; Butantan; IVAC (Institute of Vaccines and Medical Biologicals); Mikrogen; Torlak Institute of Virology, Vaccines and Sera

DTP-HepB-Hib Biological E; Janssen; LG Life Sciences; PT Bio Farma (Persero); Serum Institute of India

Arabio; Bharat Biotech; Centro de Ingeniería Genética y Biotecnología; GSK; Panacea Biotec; Shantha Biotechnics Private Limited

HepB (ped) LG Life Sciences; PT Bio Farma (Persero); Serum Institute of India

Biokangtai; China CNBG; Dalian Hissen; GSK; Janssen; Merck Vaccines; Mikrogen; NCPC GeneTech; Sanofi Pasteur MSD; VABIOTECH

IPV Bilthoven Biologicals; PT Bio Farma (Persero); Sanofi Pasteur; Shantha Biotechnics Private Limited

GSK; Institute of Medical Biology – Chinese Academy of Medical Sciences; Serum Institute of India

JE Chengdu Institute of Biological Products Co., Ltd; GPO-MBP Co., Ltd.

China CNBG; Sanofi Pasteur; VABIOTECH

Measles PT Bio Farma (Persero); Serum Institute of India Biovac SA; Mikrogen; POLYVAC (Center for Research and Production of Vaccine and Biologicals)

MMR GSK; Serum Institute of India China CNBG; Merck Vaccines; Sanofi Pasteur

MR Serum Institute of India Beijing Minhai Biotech; China CNBG

Td Sanofi Pasteur; PT Bio Farma (Persero) AJ Vaccines A/S; BB-NCIPD; Biological E; Boryung Biopharma; Butantan; GSK; InterVax; Mikrogen; Razi Institute Iran; Serum Institute of India; Torlak Institute of Virology, Vaccines and Sera

TT Biological E BB-NCIPD; Bharat Biotech; Boryung Biopharma; Finlay; GSK; InterVax; IVAC (Institute of Vaccines and Medical Biologicals); Mikrogen; PT Bio Farma (Persero); Sanofi Pasteur; Serum Institute of India; Shantha Biotechnics Private Limited; Torlak Institute of Virology, Vaccines and Sera

SEAR

DISCLAIMER

Information contained in the V3P database is provided by participating countries and/or organizations procuring on behalf of countries that have agreed to share vaccine price and procurement data with V3P. Participating countries are solely responsible for the accuracy of the data provided.

The information contained in the V3P database does not in any way imply an endorsement, certification, warranty of fitness or recommendation by WHO of any company or product for any purpose, and does not imply preference over products of a similar nature that are not mentioned. WHO furthermore does not warrant that: (1) the information is complete and/or error free; and/or that (2) the products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with the national laws and regulations of any country, including but not limited to patent laws. Inclusion of products in the database does not furthermore imply any approval by WHO of the products in question (which is the sole prerogative of national authorities). WHO will not accept any liability or responsibility whatsoever for any injury, death, loss, damage, or other prejudice of any kind that may arise as a result of, or in connection with the procurement, distribution and use of any product listed in the V3P database.